Search company, investor...
Limbix company logo


Founded Year



Series A - II | Alive

Total Raised


Last Raised

$15M | 1 yr ago

About Limbix

Limbix delivers mental health treatment to young people. It offers digital therapeutic for adolescent depression, enabling doctors to offer digital, evidence-based, therapeutic interventions, behavioral health care, and more. The company was founded in 2017 and is based in San Francisco, California.

Headquarters Location

548 Market Street PMB 91609

San Francisco, California, 94104,

United States


ESPs containing Limbix

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Healthcare Providers Tech

The companies in this market develop digital therapeutics to treat general anxiety and depression. The solutions offered by these companies include cognitive behavioral therapy apps, virtual reality interventions, biofeedback programs, and more.

Limbix named as Leader among 14 other companies, including Pear Therapeutics, Twill, and Noom.

Compete with Limbix?

Ensure that your company and products are accurately represented on our platform.

Limbix's Products & Differentiators

    Limbix Spark

    Limbix Spark will be positioned as first line treatment for adolescent depression primarily within primary care and can serve as an alternative or adjunct to antidepressant treatment. Following FDA clearance, Limbix Spark would be the first evidence-based prescription digital therapeutic designed specifically for adolescent depression.

Research containing Limbix

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Limbix in 3 CB Insights research briefs, most recently on Dec 21, 2022.

Expert Collections containing Limbix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Limbix is included in 7 Expert Collections, including AR/VR.



1,390 items

This collection includes companies creating hardware and/or software for augmented reality, virtual reality, and mixed reality applications.


Digital Health

13,158 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)


Mental Health Tech

1,406 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.


Medical Devices

9,288 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.


Health IT

7,901 items

Limbix Patents

Limbix has filed 3 patents.

The 3 most popular patent topics include:

  • Virtual reality
  • Augmented reality
  • Computer peripherals
patents chart

Application Date

Grant Date


Related Topics



Virtual reality, Mixed reality, Digital media, Multimodal interaction, Video on demand services


Application Date


Grant Date


Related Topics

Virtual reality, Mixed reality, Digital media, Multimodal interaction, Video on demand services



Latest Limbix News

How one US health plan is trailblazing access to digital therapeutics

Dec 21, 2022

Health Tech World By Jake de Medeiros, Director of Commercialization Strategy at Limbix Published Jake de Medeiros is Director of Commercialization Strategy at Limbix , the company behind SparkRX , the first digital treatment for adolescent depression currently being offered under the FDA’s Enforcement Policy. Since the FDA’s clearance of the first prescription digital therapeutic (PDT) in 2017, limited market access has been a major headwind for the category. Payers have largely deemed digital therapeutics as investigational, not to be covered or reimbursed. As a result, these evidence-based digital therapies proven to treat, manage, or prevent diseases or disorders have seen minimal real-world patient use despite their significant clinical potential. However, a recent announcement from Pittsburgh, PA based Highmark BCBS may offer the boost digital therapeutics need. In August 2022, Highmark, which covers 6 million lives across multiple states, released a Commercial Medical Policy that deemed select digital therapeutics approved by the FDA as medically necessary and reimbursable. While Highmark is not the first to cover PDTs, it is the first large commercial payer that plans to pay for them. Highmark is blazing the trail by showing a willingness to work with PDTs who have already met FDA ’s standard for clearance. Typical plans have shown trepidation and lack of acceptance toward PDTs, citing the lack of existing real-world data and cost reduction outcomes. Highmark’s policy will, ideally, cause a domino effect of plans to reconsider their PDT policy. Their decision adds legitimacy to the category and places pressure on plans whose members desire novel ways to address their medical needs. While PDTs are being developed for a broad range of indications, they show significant promise for mental health . Jake de Medeiros Disorders such as depression, anxiety, ADHD, and substance abuse are at  all-time highs in the US. However, there are simply not enough medical professionals equipped to manage these complex and often comorbid disorders. 2021 alone saw an exodus of 330,000 healthcare providers, many of which were frontline providers for mental health conditions, like paediatricians and family medicine doctors. These access issues are further compounded in areas like paediatric mental health, where child specialists are few and far between. Paediatric patients commonly experience 6-month waitlists for mental health specialists, leading to worried caregivers in need of treatment options for their children. That is why digital therapeutic companies like Limbix are developing digital treatments    specifically aimed at addressing paediatric mental health disorders. Limbix, for example, is developing SparkRx, a digital therapeutic designed to provide an evidence-based adjunct treatment intervention for adolescents aged 13-22 with symptoms of depression. SparkRx is a five-week program that delivers the core components of CBT through a self-guided mobile app. While SparkRx has been used by hundreds of patients and providers for free under the FDA Enforcement Policy for Digital Devices during COVID-19 , payer coverage will be paramount for ongoing patient access to solutions like SparkRx. Highmark’s policy decision is a pivotal stepping stone for increasing access to digital treatments across disorders and disease states. Their process and decisions will continue to serve as a framework for how digital therapeutics are evaluated and covered by other US health plans in the future. While it still may take a few more years for digital therapeutics to gain broad coverage and adoption, early access wins allow PDT manufacturers to develop a rich, real-world evidence base for clinical outcomes and engagement. This data will further solidify the rationale for covering PDTs from outcomes and cost perspectives. Manufacturers can use this information as evidence for why broad access to PDTs is vital for the well-being of health plan members. As the category gains ground in market access, PDT companies are in the process of building their pipeline and evidence base for the next generation of therapies. Early signs of good faith from leaders in healthcare, such as Highmark, further solidify the promise this industry has to offer for patients and providers in need of accessible healthcare. 60

Limbix Frequently Asked Questions (FAQ)

  • When was Limbix founded?

    Limbix was founded in 2017.

  • Where is Limbix's headquarters?

    Limbix's headquarters is located at 548 Market Street, San Francisco.

  • What is Limbix's latest funding round?

    Limbix's latest funding round is Series A - II.

  • How much did Limbix raise?

    Limbix raised a total of $24M.

  • Who are the investors of Limbix?

    Investors of Limbix include BIXINK Therapeutics, GSR Ventures, Storm Ventures, DN Capital, MVP Ventures and 18 more.

  • Who are Limbix's competitors?

    Competitors of Limbix include Xploro and 7 more.

  • What products does Limbix offer?

    Limbix's products include Limbix Spark.

  • Who are Limbix's customers?

    Customers of Limbix include KidsX.

Compare Limbix to Competitors

XRHealth Logo

XRHealth operates virtual clinics. It integrates immersive virtual reality and augmented reality (VR/AR) technology, licensed clinicians, and advanced data analytics technology on one platform, providing a comprehensive therapeutic care solution for patients. The company focuses on pain management, neurological disorders, and behavioral health. It was founded in 2016 and is based in Brookline, Massachusetts.

OxfordVR Logo

OxfordVR is a digital therapeutics company that develops evidence-based immersive treatments using virtual reality for serious mental illness. Its treatments are reshaping the future of mental healthcare, fusing deep scientific evidence with emerging technology to create powerful new therapeutic tools for some of the world’s most challenging mental health conditions. The company was founded in 2016 and is based in Austin, Texas.


C2Care designs therapeutic solutions based on virtual reality in order to immerse the patient in an environment that creates certain stress. The goal is to make virtual exposure therapies accessible to health professionals and more specifically to mental health professionals.

AppliedVR Logo

AppliedVR, which was founded in 2015, offers virtual reality-based treatments for chronic pain management. The company's EaseVRx solution, which aims to combine cognitive-behavioral therapies with mindfulness exercises, was designated by the FDA as a virtual reality (VR) prescription therapy for treatment-resistant fibromyalgia and chronic intractable lower back pain. The platform is designed to engage the patient during all stages of procedures in hospitals and surgical centers, offering patients drug-free alternatives to manage pain and anxiety associated with medical procedures.

Oui Therapeutics

Oui Therapeutics offers a mobile app aimed at suicide prevention. The app would be prescribed to patients who have experienced a suicidal crisis to help teach skills to reduce risks. The company was founded in 2018 and is based in New Haven, Connecticut.

BehaVR Logo

BehaVR builds evidence-based, immersive and digital therapeutics. Its suite of therapeutics offers access to treatments on a spectrum across mental wellness and mental and behavioral conditions, including validated treatments for serious mental illness. The company delivers these treatments on an integrated platform that simplifies the patient experience, enables clinician oversight, and generates patient-specific care plans and measurable outcomes. BehaVR was founded in 2016 and is based in Elizabethtown, Kentucky.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.